脑室内注射尼莫地平治疗动脉瘤性蛛网膜下腔出血：NEWTON 1/2a期研究结果 - Suppr

Suppr

超能文献

Intraventricular Nimodipine for Aneurysmal Subarachnoid Hemorrhage: Results of the NEWTON Phase 1/2a Study.

作者信息

Zussman Benjamin, Weiner Gregory M, Ducruet Andrew

机构信息

University of Pittsburgh Medical Center Pittsburgh, Pennsylvania.

Barrow Neurological Institute Phoenix, Arizona.

出版信息

Neurosurgery. 2017 Jul 1;81(1):N3-N4. doi: 10.1093/neuros/nyx260.

DOI:10.1093/neuros/nyx260

PMID:28873993

Abstract

摘要

相似文献

Intraventricular Nimodipine for Aneurysmal Subarachnoid Hemorrhage: Results of the NEWTON Phase 1/2a Study.脑室内注射尼莫地平治疗动脉瘤性蛛网膜下腔出血：NEWTON 1/2a期研究结果

Neurosurgery. 2017 Jul 1;81(1):N3-N4. doi: 10.1093/neuros/nyx260.

Randomized, Open-Label, Phase 1/2a Study to Determine the Maximum Tolerated Dose of Intraventricular Sustained Release Nimodipine for Subarachnoid Hemorrhage (NEWTON [Nimodipine Microparticles to Enhance Recovery While Reducing Toxicity After Subarachnoid Hemorrhage]).一项随机、开放标签的1/2a期研究，以确定脑室内持续释放尼莫地平用于蛛网膜下腔出血的最大耐受剂量（NEWTON [尼莫地平微粒在蛛网膜下腔出血后增强恢复并降低毒性]）

Stroke. 2017 Jan;48(1):145-151. doi: 10.1161/STROKEAHA.116.014250. Epub 2016 Dec 8.

NEWTON: Nimodipine Microparticles to Enhance Recovery While Reducing Toxicity After Subarachnoid Hemorrhage.牛顿：尼莫地平微粒可在减少蛛网膜下腔出血后毒性的同时促进恢复。

Neurocrit Care. 2015 Oct;23(2):274-84. doi: 10.1007/s12028-015-0112-2.

Intrathecal application of the nimodipine slow-release microparticle system eg-1962 for prevention of delayed cerebral ischemia and improvement of outcome after aneurysmal subarachnoid hemorrhage.鞘内应用尼莫地平缓释微粒系统eg-1962预防动脉瘤性蛛网膜下腔出血后的迟发性脑缺血并改善预后。

Acta Neurochir Suppl. 2015;120:281-6. doi: 10.1007/978-3-319-04981-6_47.

Intravenous magnesium versus nimodipine in the treatment of patients with aneurysmal subarachnoid hemorrhage: a randomized study.静脉注射镁剂与尼莫地平治疗动脉瘤性蛛网膜下腔出血患者的随机研究

Neurosurgery. 2006 Jun;58(6):1054-65; discussion 1054-65. doi: 10.1227/01.NEU.0000215868.40441.D9.

The efficacy of an abbreviated course of nimodipine in patients with good-grade aneurysmal subarachnoid hemorrhage.尼莫地平短疗程治疗对Hunt-Hess分级良好的动脉瘤性蛛网膜下腔出血患者的疗效

J Neurosurg. 1999 Feb;90(2):203-6. doi: 10.3171/jns.1999.90.2.0203.

Nimodipine Dose Reductions in the Treatment of Patients with Aneurysmal Subarachnoid Hemorrhage.尼莫地平剂量降低在动脉瘤性蛛网膜下腔出血患者治疗中的应用

Neurocrit Care. 2016 Aug;25(1):29-39. doi: 10.1007/s12028-015-0230-x.

Effects of nimodipine on cerebral vasospasm in patients with aneurysmal subarachnoid hemorrhage treated by endovascular coiling.尼莫地平对血管内栓塞治疗的颅内动脉瘤性蛛网膜下腔出血患者脑血管痉挛的影响。

Adv Clin Exp Med. 2013 Jan-Feb;22(1):101-9.

The predictors and clinical impact of intraventricular hemorrhage in patients with aneurysmal subarachnoid hemorrhage.动脉瘤性蛛网膜下腔出血患者脑室内出血的预测因素及临床影响

Int J Stroke. 2016 Jan;11(1):68-76. doi: 10.1177/1747493015607518.

A randomized outcome study of enteral versus intravenous nimodipine in 171 patients after acute aneurysmal subarachnoid hemorrhage.一项 171 例急性蛛网膜下腔出血后肠内与静脉尼莫地平随机结局研究。

World Neurosurg. 2012 Jul;78(1-2):101-9. doi: 10.1016/j.wneu.2011.09.030. Epub 2011 Nov 1.

引用本文的文献

Clinical Pharmacology of Clazosentan, a Selective Endothelin A Receptor Antagonist for the Prevention and Treatment of aSAH-Related Cerebral Vasospasm.氯唑沙坦的临床药理学，一种用于预防和治疗蛛网膜下腔出血相关脑血管痉挛的选择性内皮素A受体拮抗剂。

Front Pharmacol. 2021 Feb 4;11:628956. doi: 10.3389/fphar.2020.628956. eCollection 2020.

Incidence of Arterial Hypotension in Patients Receiving Peroral or Continuous Intra-arterial Nimodipine After Aneurysmal or Perimesencephalic Subarachnoid Hemorrhage.口服或持续经动脉尼莫地平治疗颅内动脉瘤或中脑周围蛛网膜下腔出血后患者的动脉低血压发生率。

Neurocrit Care. 2019 Aug;31(1):32-39. doi: 10.1007/s12028-019-00676-w.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验